The therapeutic ecacy of synthetic inhibitors of matrixmetalloproteinases (MMPs) in various cancers has been demonstrated. A novel inhibitor, Ro 28-2653, with high selectivity for MMP2, MMP9 and membrane type 1-MMP was evaluated in an orthotopic prostate cancer rat model. Ecacy was determined by recording tumor growth and survival endpoints. Prostate cancer was induced by inoculating R3327 Dunning tumor cells (MatLyLu) into the ventral lobe of the prostates of 148 Copenhagen rats. Daily oral treatment with Ro 28-2653 (10 ± 300 mg/kg per day) was started on day 1 or on day 6 after tumor cell injection. Animals were sacri®ced on day 20 for determination of tumor weights. For survival studies, rats received daily oral Ro 28-2653 (100 mg/kg per day) or vehicle for up to 30 days. Tumor induction was successful in 100% of the animals. Ro 28-2653 reproducibly reduced the tumor weights by up to 90% in a dose-dependent manner. In addition, an inhibitory eect in rats with established tumors (treatment start at day 6) was shown. A signi®cantly prolonged survival of Ro 28-2653-treated rats was also demonstrated. Selective inhibition of MMP activity is a novel therapeutic approach, which bears promise for studies in patients with prostate cancer.
Introduction
Cancer of the prostate is the most common malignancy in men and results in a high degree of morbidity and mortality. In 2001 an estimated 198 100 new cases of prostate cancer will be diagnosed with 31 500 estimated deaths in the USA (Greenlee et al., 2001) . For prostate cancer patients with localized disease, radical prostatectomy or radiation therapy are the treatments of choice (Walsh, 2000) . In general, prognosis is strongly related to tumor invasion of the prostatic capsule and occurrence of metastases to lymph nodes or distant organs. Compared to most other cancers treatment options are strongly limited and less eective in patients with advanced or relapsing disease. In advanced prostate cancer, anti-androgen hormone therapy is an established treatment to inhibit tumor progression for a limited time (Oh and Kanto, 1998) . However, these patients are not curable and tumor progression can ultimately not be prevented. This fact supports enormous interest in the investigation of more eective methods for the treatment of advanced prostate cancer. A promising strategy is the application of synthetic inhibitors of matrix-metalloproteinases (MMPs) (Brown and Giavazzi, 1995) .
MMPs belong to a growing family of zinc atomdependent endogenous proteases with the ability to degrade various components of extracellular matrix, such as collagen, ®bronectin and elastin (Liotta and Stetler-Stevenson, 1991) . Because of their occurrence in a variety of tissues, these proteases are considered key enzymes in physiological processes including wound healing, tissue remodeling and -repair, bone resorption and trophoblast invasion (Crawford and Matrisian, 1994; Mignatti and Rifkin, 1996) . Moreover, MMPs have been demonstrated to play a crucial role in pathological conditions such as rheumatoid arthritis and cancer (Anderson et al., 1995; Kim et al., 1998) .
Multistep processes such as tumor invasion and metastatic spread involve the destruction of tissue integrity including breakdown of the basement membrane and loss of cell adhesion. Thus, MMPs are critical for entry of tumor cells into lymphatic and blood vessels and the colonization of distant organs (Rabbani, 1998) . Tumor progression and growth require the ability to promote neo-vascularization. Tumor cells and surrounding stromal cells produce MMPs. Normally, the proteolytic activity of MMPs is tightly regulated by various mechanisms including the secretion of MMP precursors that require cleavage for activation and the natural inhibition of activated enzymes by speci®c regulatory proteins, known as tissue inhibitors of metalloproteinases (TIMPs) (Stetler-Stevenson et al., 1989) . Thus, the balance between MMP and TIMP may be viewed as positive and negative modulation of tumor invasion and metastatic processes.
The importance of MMPs and their inhibitors has been demonstrated in a large body of studies. Enhanced expression of MMPs and TIMPs has been correlated with the increased invasiveness of various human cancers such as of the breast, colon, stomach and kidney (Davies et al., 1993; Lein et al., 2000) . Altered levels of MMPs and TIMPs and their importance have been elucidated in prostate cancer (Lokeshwar et al., 1993) .
All these facts together allow synthetic inhibitors of MMPs to be regarded as potential drugs. Pharmacological inhibitors of MMPs could be an innovative class of therapeutic agents to control tumor progression and metastases (Lein et al., 2000a; Eccles et al., 1996; Price et al., 1999) . In the past few years, synthetic MMP inhibitors have undergone rapid clinical development. MMP inhibitors like Batimastat or Marimastat have demonstrated pre-clinical in vivo activity (Rothenberg et al., 1999) . Both tumor growth reduction and inhibition of metastases could be observed. We used an established orthotopic prostate cancer model in order to evaluate the therapeutic capacity of a newly developed inhibitor, Ro 28-2653, with high selectivity for MMP2, MMP9 and membrane type 1-MMP. The pyrimidine-2,4,6,-triones like Ro 28-2653 as a completely new class of MMP inhibitors are much more speci®c then the most MMP inhibitors currently under development (Grams et al., 2001) . These compounds bind to the MMPs in a manner that saturates nearly all possible interactions of the pyrimidine core moiety to the protein. The IC 50 of Ro 28-2653 are the following: MMP2 (10 nM), MMP9 (12 nM), MMP14 (10 nM), MMP8 (12 nM), MMP3 (1200 nM), MMP1 (16 000 nM). Moreover, this novel inhibitor have been compared with other well established compound such as Batimastat, Prinomastat (Ag 3340) or BAY 12-9566 development (Grams et al., 2001) . A high selectivity against MMP2 and MMP9 could be shown.
The Dunning R3327 MatLyLu tumor was developed as a model system to study prostate cancer progression (Lucia et al., 1998) . R3327 MatLyLu Dunning tumor is an androgen-independent, highly metastatic, and anaplastic rat prostate tumor. This tumor of immunocompetent male Copenhagen rats shows close similarities with human prostate cancer with regard to its behavior under hormone therapy, chemotherapy and/ or radiation therapy. Signi®cant expression of MMP9 in tumor tissue and blood has been demonstrated in Dunning R3327 MatLyLu tumor-bearing animals (Lein et al., 2000b) . As demonstrated in this previous study, we used the orthotopic inoculation of tumor cells. Orthotopic tumor implantation is regarded as highly relevant for future clinical studies. In the present study, we documented the ability of Ro 28-2653 to reduce tumor growth and extend survival time of tumor-bearing animals.
Results

In vitro experiments
The exposure of R3327 MatLyLu Dunning tumor cells to 40, 200, 1000 or 5000 ng/ml Ro 28-2653 for 24, 48, 72, 96 or 120 h had no signi®cant eect on the proliferation as compared with vehicle and as determined by XTT assay.
Tumor growth in untreated tumor-bearing rats
The surgical procedure and tumor cell injection were well tolerated. In all rats, orthotopic tumors were successfully implanted by tumor cell injection. In untreated control animals median tumor weights at 6 (n=5) and 20 days (n=21) after tumor cell inoculation were 0.17 g (range: 0.14 ± 0.18 g) and 17.2 g (range: 11.8 ± 24.0 g), respectively.
Effect of Ro 28-2653 on orthotopic tumor growth
Starting on days 1 or 6 after tumor cell inoculation, rats were treated with dierent doses (10 ± 300 mg/kg/ day) of Ro 28-2653 for 20 or 15 days.
Rats (n=4) treated with 300 mg/kg/day Ro 28-2653 rapidly lost body weight and died between day 5 and day 7. However, the daily oral application of Ro 28-2653 including the concentration of 200 mg/kg/day was well tolerated by all other animals without a signi®cant loss of body weight or other indicators of compromise. Oral daily treatment with Ro 28-2653 at doses of 200 mg/kg/day or less exhibited no noticeable toxic side eects.
The eect of Ro 28-2653 in reducing orthotopic tumor growth was evaluated by determination of tumor weights at 20 days after inoculation. Tumor weights were signi®cantly dierent between treated and untreated control groups or animals receiving vehicle alone. Individual tumor weights and medians are given in Figure 1a 
Effect of Ro 28-2653 on survival in orthotopic tumor model
Additional experiments were performed to answer the question, whether Ro 28-2653-mediated local tumor control resulted in increased survival rates. A total of 40 rats were enrolled in the survival experiment using 100 mg/kg/day Ro 28-2653. Starting oral application on days 1, 3 or 6 after tumor cell injection, animals received Ro 28-2653 for up to day 30 except of one group that was only treated between days 1 and 19. On day 30, all living rats (n=10) were sacri®ced because of excessive tumor load. Animals treated with Ro 28-2653 survived signi®-cantly longer than vehicle-treated controls independently of treatment duration (Table 1) . No dierences within the Ro 28-2653 treated animals or vehicle groups were observed. Therefore, survival curves (Kaplan ± Meier) receiving vehicle were combined as were those receiving drug (Figure 2 ).
Ro 28-2653 plasma concentrations
In vehicle-treated rats, in 30 mg/kg/day Ro 28-2653 treated rats and in 100 mg/kg/day Ro 28-2653 treated rats (two dierent groups), Ro 28-2653 plasma levels were determined. Vehicle or Ro 28-2653 were administered daily between day 1 and day 20 after tumor cell injection. Before (day 0) and after tumor cell injection at days 9, 10 and 20 blood samples were collected. Mean plasma concentrations are given in Table 2 . In 30 mg/kg/ day Ro 28-2653 treated animals mean plasma concentrations between 29.6 and 49.1 mg/l and in 100 mg/kg/ day Ro 28-2653 treated groups mean plasma concentrations between 83.5 and 122.0 mg/l were measured.
Histopathological observations
The tumors of the control animals ( Figure 3a ) grew as solid high malignant carcinoma invading the connective tissue, blood-and lymph vessels, as well as sometimes the urethra. The tumors showed a very high mitotic activity. The tumor cells revealed a polygonal cell structure with basophilic cytoplasm and polymorphy of the nuclei. Interstitial connective tissue was rare in the tumors. There wasn't a clear border or capsule in the periphery of the tumors. The tumors showed slight multiple necrotic area.
The primary tumor in the prostate of the animals treated with 100 mg/kg/day Ro 28-2653 ( Figure 3b ) were signi®cantly smaller in size as in the controls. The primary tumors of these animals showed distinct regressive changes in form of severe to extreme necrosis compared to the changes in the control animals. There were only small parts of active tumor cells which were found along or near the intratumoral blood vessels. However, there were no dierences in the growth pattern and in the mitotic activity in the drug treated animals compared to the controls. The content of blood vessels in the periphery of the tumors of the drug treated animals revealed slightly lower contents as in the controls.
Discussion
The present study demonstrated ecacy of the synthetic MMP inhibitor Ro 28-2653 in the treatment Both MMP9 and MMP2 seem to be strongly implicated in tumor progression. Increased MMP9 levels have been reported in various malignancies (Rothenberg et al., 1999; Wood et al., 1997) . As shown previously, increased MMP9 expression has also been demonstrated in orthotopic tumor model of Copenhagen rats (Lein et al., 2000b) . Moreover, changes in MMP9 expression have also been observed in a few studies regarding human prostatic cell cultures and tissue samples (Still et al., 2000; Wood et al., 1997) . Increased concentrations of MMP9 were found in malignant tissue compared to benign tissue and in supernatants of cell cultures of cancerous tissue samples in comparison to cultures derived from benign tissue (Festuccia et al., 1996) .
Ro 28-2653 has been developed as a selective MMP inhibitor with some speci®city for MMP2, 9 and MT1-MMP. The observations regarding MMP9 expression in Dunning tumor tissue and the present data are consistent with the activity of Ro 28-2653 in vivo. Ro 28-2653 was obviously more ecient to block local tumor progression when treatments were started immediately after tumor cell inoculation. Tumor weights reduced by up to 90% were observed when treatment started on day 1 as compared with a maximal reduction of 70% when MMP inhibition was initiated on day 6 (Figure 1) . Together with the positive correlation between tumor weights and administered Ro 28-2653 doses, this observation suggests dose dependence. Moreover, these ®ndings also demonstrate ecacy of Ro 28-2653 in rats with established local tumors. This resembles the clinical situation where treatment using MMP inhibitors is initiated in patients with established prostate cancer.
When Ro 28-2653 was added to the MatLyLu cell culture medium, eects on proliferation of MatLyLu cells could not be observed at concentrations up to 5000 ng/ml. These in vitro data are in close agreement with our previous studies using the MMP inhibitor Batimastat in this cell line (Lein et al., 2000a) . Similarly, Batimastat had an eect on cell proliferation only at very high concentrations. These results prove that Ro 28-2653 has no direct anti-proliferative eects on tumor cells.
The well-characterized MatLyLu Dunning tumor model was chosen for the study because the tumor is relatively resistant to standard prostate cancer therapies such as hormone ablation. According to the`First International Workshop on Animal Models of Prostate Cancer' based on a large body of information, the Dunning R3327 system has been recommended for imaging and therapeutic studies in prostate cancer (Lucia et al., 1998) .
The extreme necrosis of the treated tumors with a lower content of blood vessels in the tumor, speci®cally in the periphery of the tumors gives a hind that the compound eect is caused by an antiangiogenetic activity of the compound. This corroborates with the fact, that there were no morphologic discrepancies between the remaining tumor cells and the controls. These occurred only as a small string along the still intact intratumoral blood vessels. This must be seen in contrast to the conventional cytotoxic chemotherapeutics. They produce the strongest eect in the close vicinity of the blood vessels due to the fact, that the concentration of the substances is mostly at the highest around that area. Thus, a large body of studies suggest that synthetic MMP inhibitors could have an important role in the future treatment of cancer (Zucker et al., 2000) . Preclinical data suggest that a reduction in the rate of tumor growth and metastasis can be achieved. However, the future role of MMP inhibitors will have to be based on randomized double-blind studies proving reproducible ecacy with tolerable or acceptable toxicity in malignancies alone or in combination with established agent. Nevertheless, the toxicity of MMP inhibitors has to be elaborated in adequate trials.
In the past years synthetic MMP inhibitors have undergone rapid clinical development. The therapeutic potential of these synthetic inhibitors could result in a new class of anti-cancer agents with a broad ®eld of application. Although a variety of studies have shown the ability of MMP inhibitors to inhibit tumor progression, the underlying molecular mechanism responsible for these eects remains poorly characterized. In 1994, the ®rst MMP-inhibitor to enter clinical testing was Batimastat, a hydroxamic acid derivative that mimics the peptide structure of natural substrates. However, administration was limited by the poor solubility of Batimastat (Hidalgo and Eckhardt, 2001; Macaulay et al., 1999) . Direct injection into the abdomen or pleural space was necessary. Despite of these limitations, preliminary studies demonstrated reduced need for thoracentesis or paracentesis in patients with malignant disease. Side eects and limited bio-availability prevented further clinical application. Our own data supported the eect of the broad spectrum MMP inhibitor Batimastat in a previous study in Dunning tumors, too (Lein et al., 2000a) . In this study, we showed that Batimastat is capable of limiting orthotopic rat tumor progression by up to 50%.
Because of the almost complete insolubility of Batimastat more soluble agents have been developed. Based on the hypothesis that only the continuous presence of MMP inhibitor in tumor tissue can inhibit cancer progression, synthetic inhibitors should be given orally making them suitable for chronic administration. Such a potential drug is the hydroxamic acid analog Marimastat with sucient oral bio-availability (Steward and Thomas, 2000) . In human phase I/II trials a signi®cant eect in reducing the rate of rise in dierent tumor markers could be demonstrated (Steward, 1999) . Moreover, a tendency towards prolonged survival combined with marker eect was observed. Most encouraging phase II studies were performed in inoperable gastric cancer patients (Tierney et al., 1999) . Despite diculties in interpreting study design and endpoints, clinical trials demonstrated a possible biological activity of this non-speci®c inhibitor of MMPs (Fielding et al., 2000) . Interestingly, in a study with hormone refractory prostate cancer patients treatment with Marimastat yielded in a 55% PSA reduction (Boasberg et al., 1997) . A signi®cant PSA decrease is generally accepted as a sign of tumor growth inhibition in prostate cancer patients.
The focus of current studies is to establish whether synthetic MMP inhibitors improve the progression-free interval and survival in a variety of cancer diseases. Another more selective MMP inhibitor is the hydroxamic acid derivative Ag 3340 . However, in advanced prostate cancer and non small cell lung cancer, Prinomastat (Ag 3340) did not demonstrate clinical eciency (Shalinsky et al., 2000) .
The results of dierent Phase III clinical trails using Marimastat, BAY 12-9566 and Prinomastat have reported (Zucker et al., 2000) . In various advanced cancer entities clinical ecacy could not be demonstrated. Therefore, some drug studies have been discontinued, and based on accumulated data, future projects should be performed on early stage cancer patients and MMP inhibitors should be applied combined with chemotherapy (Zucker et al., 2000) .
We believe that our data obtained in the present study justify further evaluation of Ro 28-2653. After possible successful evaluation of tolerability and safety, Ro 28-2653 could be co-administered in hormonerefractory prostate cancer patients (or in early stage) combined with cytotoxic agents. For the group of prostate cancer patients after failure of hormonal therapy, an established eective standard therapy is not available. Various cytotoxic chemotherapy strategies for clinical development are being studied (Smith et al., 1999) . Therefore, hormone-refractory prostate cancer seems to be a ®tting tumor entity for evaluation of the ecacy of Ro 28-2653 in humans, at ®rst.
Taken together, this animal study documents the ability of the newly developed MMP inhibitor Ro 28-2653 to drastically inhibit orthotopic prostate cancer growth in animals. These ®ndings encourage the use of this new class of agents as adjuvant or palliative treatment in prostate cancer patients.
Materials and methods
Cell line
The R3327 Dunning tumor cell (MatLyLu) line was a generous gift of Dr Heston (Memorial Sloan-Kettering Cancer Center, NY, USA). Tumor cells were maintained in RPMI 1640 (Bio Whitaker, Verviers, Belgium) with Lglutamine supplemented with 10% fetal calf serum and were cultivated at 378C in a humidi®ed atmosphere of 5 % CO 2 as previously described (Lubaro et al., 1980) .
MMP-inhibitor
The synthetic compound Ro 28-2653 (5-biphenyl-4-yl-5-[4-(-nitro-phenyl)-piperazin-1-yl]-pyrimidine-2,4,6-trione) was provided by Roche Diagnostics GmbH, Pharma Research (Penzberg, Germany).
In vitro cell proliferation
Tumor cells were seeded onto 96-well microtiter plates at 500 cells/well in 200 ml of the medium mentioned above and allowed to adhere during overnight incubation at 378C and 5% CO 2 . Twenty-four hours (day 0) after seeding, medium was exchanged for zero, 40, 200, 1000 and 5000 ng/ml Ro 28-2653 in culture medium with control wells. Every 48 h thereafter, the medium was changed. For determination of tumor cell viability, the XTT (sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis-(4-methoxy-6-nitro) benzene sulfonic acid hydrate) assay was used. The formazan absorbance was read on a Microplate Reader (Anthos HT3, Anthos Labtec Instruments, Salzburg, Austria), using 540 or 620 nm band pass ®lters. In vitro experiments were run in quadruplicate wells and repeated twice.
Tumor implantation
Animal care was in accordance with institutional guidelines. Male Copenhagen rats weighing 180 ± 220 g were obtained from Charles River (Sulzfeld, Germany). Dunning tumors were implanted into the prostate of 148 animals. This tumor model has been described in detail. Shortly, Dunning tumor cells were trypsinized and resuspended in fresh complete medium at a density of 10 6 ml. Animals were randomly selected for the groups, numbered and maintained under identical conditions. For tumor cell injection the animals were anesthetized with an intraperitoneal injection of ketamine and xylocaine. One hundred thousand tumor cells (in 0.1 ml) were injected into the ventral prostatic lobe exposed by a suprapubic transverse incision. To avoid any possible leakage of cell material, a cotton-tipped applicator with iodine solution was placed over the injection site before withdrawal of the needle and held in place for approximately 1 min. All animals were monitored daily for body weight.
MMP-inhibitor treatment
To examine the eect of the MMP inhibitor on tumor weight, animals were treated daily with Ro 28-2653 for 20 and 15 days, respectively, starting from day 1 and day 6 after tumor cell injection. This procedure was chosen to evaluate the in¯uence of the local tumor mass within the prostate on the treatment success. Controls included tumor-bearing animals receiving saline alone or vehicle (0.2% sodiumcarboxymethylcellulose). The drug or vehicle was administered orally by gastric catheter. All animals were sacri®ced on day 20, and tumors were excised, surrounding tissue removed and immediately weighed. In a second series the eect of Ro 28-2653 on survival of animals was studied in groups of 5 to 6 rats. Treatment was initiated on days 1, 3, 6 and continued until death or day 30. One additional group received treatment between days 1 and 19 only. Controls included vehicle controls as described above.
Determination of Ro 28-2653 plasma concentrations
For retro-orbital blood collection rats were shortly anaesthetized. Plasma levels of Ro 28-2653 were analyzed after extraction with diethylether. The solvent was evaporated and the pellet was suspended in KH 2 PO 4 (0.01 M, pH 3.0)/ acetonitril (50 : 50, solvent A). Ro 28-2653 content was determined by an HPLC procedure (HP 1100, Waters Symmetry C18 column) using a gradient of KH 2 PO 4 (0.01 M, pH 3.0)/acetonitril (20 : 80) in solvent.
Histopathologic examination
The primary tumors of the control animals as well as the animals treated with 100 mg/kg/day Ro 28-2653 were immediately ®xed in 3.8% of formaldehyde solution for histological examinations. After ®xation, the tumors were divided in two parts and were embedded in paraplast. The histological samples were stained by the hematoxilin-eosin technique.
Statistical analysis
Statistical evaluations were performed using the statistical program GraphPad Prism (GraphPad, San Diego, CA, USA). The one-way analysis of variance (ANOVA), the Kruskal ± Wallis nonparametric analysis of variance and the Kaplan ± Meier test for survival were used. The log rank test was applied to compare survival rates between subgroups. Dierences of P50.05 were considered statistically signi®-cant.
